Cargando…
A multicenter, open-label, phase III study of Abcertin in Gaucher disease: Erratum
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6112868/ https://www.ncbi.nlm.nih.gov/pubmed/30113507 http://dx.doi.org/10.1097/MD.0000000000012066 |
Ejemplares similares
-
A multicenter, open-label, phase III study of Abcertin in Gaucher disease
por: Lee, Beom Hee, et al.
Publicado: (2017) -
Erratum: A Phase 2 Multi-center, Open-label, Switch-over Trial to Evaluate the Safety and Efficacy of Abcertin® in Patients with Type 1 Gaucher Disease
por: Choi, Jin-Ho, et al.
Publicado: (2015) -
A Phase 2 Multi-center, Open-label, Switch-over Trial to Evaluate the Safety and Efficacy of Abcertin® in Patients with Type 1 Gaucher Disease
por: Choi, Jin-Ho, et al.
Publicado: (2015) -
Erratum for Screening for Gaucher Disease Using Dried Blood Spot Tests: A Japanese Multicenter, Cross-sectional Survey
por: Miyamoto, Toshihiro, et al.
Publicado: (2021) -
Erratum to: Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment
por: Weinreb, Neal J., et al.
Publicado: (2013)